HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grace, M. E. Articles by Grabowski, G. A. Search for Related Content PubMed PubMed Citation Articles by Grace, M. E. Articles by Grabowski, G. A. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 265, Issue 12, 6827-6835, Apr, 1990

Analyses of catalytic activity and inhibitor binding of human acid beta- glucosidase by site-directed mutagenesis. Identification of residues critical to catalysis and evidence for causality of two Ashkenazi Jewish Gaucher disease type 1 mutations

ME Grace, PN Graves, FI Smith and GA Grabowski
Division of Medical and Molecular Genetics, Mount Sinai School of Medicine, New York, New York 10029.

Analyses of catalytic properties and inhibitor binding were conducted to investigate the molecular basis of active site function of human acid beta-glucosidases (EC 3.2.1.45) expressed from normal and Gaucher disease Type 1 alleles. Comparative studies were conducted with enzymes expressed from natural (spleen and fibroblasts) alleles or from mutagenized cDNAs in Spodoptera frugiperda (Sf9) cells using the baculovirus expression system. Mutant cDNAs containing Thr43 to Lys43 (beta-GlcThr43----Lys) and Asp358 to Glu358 (beta-GlcAsp358----Glu) substitutions and two cDNAs containing Ashkenazi Jewish Gaucher disease Type 1 mutations, Arg120 to Gln120 (beta-GlcArg120----Gln) and Asn370 to Ser370 (beta-GlcAsn370----Ser) were expressed and the gene products characterized by enzymatic, immunologic, and inhibitor studies. Genotypes at the acid beta-glucosidase locus in selected Gaucher disease Type 1 patients were determined by allele-specific oligonucleotide hybridization of amplified genomic DNA. Compared with normal, recombinant or natural enzymes expressed from beta-GlcAsn370---- Ser alleles had about 2-5-fold decreased specific activity based on CRIM (cross-reacting immunologic material). The beta-GlcArg120----Gln cDNA expressed catalytically inactive CRIM in Sf9; consistent with the 9-fold decreased CRIM-specific activity of the natural enzyme from a beta-GlcArg120----Gln/beta-GlcAsn370----Ser genetic compound. The beta- GlcAsp358----Glu cDNA expressed catalytically inactive CRIM in Sf9 cells. The presence of natural or recombinant enzyme expressed from beta-GlcAsn370----Ser alleles was sufficient to confer 3-5-fold increased IC50 values for deoxynojirimycin, glucosylsphingosine, and N- alkyl-glucosylamine derivatives. Progress curves for inhibition by the slow-tight binding N-alkyl-glucosylamines indicated that the beta-Glc- Asn370----Ser mutation did not alter a conformational change induced by these reaction intermediate analogues. These results provide evidence that the beta-GlcArg120----Gln and beta-GlcAsn370----Ser mutations found in Gaucher disease Type 1 patient genomes are the molecular bases of the enzymatic dysfunction. In addition, the region including Arg120 and that encompassing Asp358 and Asn370 contain residues critical to active site formation or participation in the catalytic mechanism.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. A. Steet, S. Chung, B. Wustman, A. Powe, H. Do, and S. A. Kornfeld The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms PNAS, September 12, 2006; 103(37): 13813 - 13818. [Abstract] [Full Text] [PDF]

				B. Liou, A. Kazimierczuk, M. Zhang, C. R. Scott, R. S. Hegde, and G. A. Grabowski Analyses of Variant Acid beta-Glucosidases: EFFECTS OF GAUCHER DISEASE MUTATIONS J. Biol. Chem., February 17, 2006; 281(7): 4242 - 4253. [Abstract] [Full Text] [PDF]

				Y. Sun, X. Qi, and G. A. Grabowski Saposin C Is Required for Normal Resistance of Acid {beta}-Glucosidase to Proteolytic Degradation J. Biol. Chem., August 22, 2003; 278(34): 31918 - 31923. [Abstract] [Full Text] [PDF]

				G. N. Sando, E. J. Howard, and K. C. Madison Induction of Ceramide Glucosyltransferase Activity in Cultured Human Keratinocytes. CORRELATION WITH CULTURE DIFFERENTIATION J. Biol. Chem., September 6, 1996; 271(36): 22044 - 22051. [Abstract] [Full Text] [PDF]

				S. Sheriff, H. Du, and G. A. Grabowski Characterization of Lysosomal Acid Lipase by Site-directed Mutagenesis and Heterologous Expression J. Biol. Chem., November 17, 1995; 270(46): 27766 - 27772. [Abstract] [Full Text] [PDF]

				E Beutler Gaucher disease: new molecular approaches to diagnosis and treatment Science, May 8, 1992; 256(5058): 794 - 799. [Abstract] [PDF]